Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne,
NY 10532
Phone: 914-347-4300
Fax: 914-347-4560
Web Site: http://www.acorda.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The companys lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Dr. Ron Cohen M.D., 54
Founder, Chairman, Chief Exec. Officer and Pres |
$
668.00K |
$
3.39M | Mr. David Lawrence M.B.A., 54
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A | Ms. Jane Wasman J.D., 54
Exec. VP, Gen. Counsel and Corp. Sec. |
N/A
| N/A | Dr. Andrew R. Blight Ph.D., 59
Chief Scientific Officer |
N/A
| N/A | Dr. Thomas C. Wessel M.D, Ph.D., 54
Chief Medical Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
Profile
Reuters offers more in-depth
